Epidermal growth factor receptors (EGFR) are overexpressed in pancreatic cancers; however, PDAC is resistant to anti‐EGFR monotherapies and combination therapies.66, 67 Abolishment of EGFR transduction is compensated by integrin β‐1‐driven Src‐Akt signaling that promotes cell survival. Here, EGFR is linked to pancreatic neoplasm.